| Divers | | |
| Définition: Définition: Syndrome prémenstruel (SPM). 10ème révision de la Classification internationale des maladies .. cacher .... voir plus ..
Un seul des symptômes suivants est suffisant pour le diagnostic de SPM:
Inconfort physiologique modéré
Ballonnements
Prise de poids
Sensibilité des seins
Gonflement de mains et de pieds
Maux et douleurs
Mauvaise concentration
Perturbations de sommeil
Changement d'appétit
Il existe 4 modèles temporels différents dans l'apparition du syndrome prémenstruel :
- fin de phase lutéale
- toute la phase lutéale
- péri-ovulatoire et fin de phase lutéale
- toute la phase lutéale et début de cycle suivant
(voir la figure ci-contre, from A Practical Guide to Premenstrual Dysphoric Disorder: The Expert Consensus Guidelines. The McGraw-Hill Companies, 2001)
... lire plus sur ce sujet dans un nouvel onglet.... |  | |
| Traitement concernée : | | |
| Thérapie coopérative de remplacement de la progestérone : de cette manière, la progestérone est toujours administrée après l'ovulation et l’administration est toujours arrêtée avant l'apparition des règles. Effectuée ainsi, la supplémentation par la progestérone ou soutien de la phase lutéale, est réalisée en synchronisation avec la production de progestérone par la femme elle-même, au cours de la phase post-ovulatoire du cycle.
La thérapie coopérative de remplacement de la progestérone permet de préserver la synchronie du cycle et est thérapeutique.
D'après le livre de T Hilgers: En octobre 2001, le BMJ a publié une revue systématique de l'efficacité de la progestérone et des progestagènes [] dans la gestion du syndrome prémenstruel. Cette étude a conclu que les résultats de leurs méta-analyses [] n'était pas en faveur de l'utilisation de la progestérone ou des progestatifs pour la gestion des SPM.
Cette étude systématique n'a pas abordé la question du moment de la prise de la progestérone au cours du cycle menstruel.
La prise de la progestérone pendant la phase luteale est une question extrêmement importante dans l'évaluation et le traitement . [] Il est à noter que l'étude qui a produit des résultats présentant une amélioration significative avec la progestérone a utilisé une administration de progestérone correctement programmée au cours du cycle menstruel.
Thérapie coopérative de remplacement de la progestérone (et éventuellement des estrogènes) .. cacher .... voir plus ..
Le problème le plus critique est le moment du cycle menstruel. La progestérone (et / ou les oestrogènes) ne fonctionnera pas si elle n'est pas administrée au bon moment du cycle menstruel. Ainsi, le cycle doit être correctement ciblé (par l'observation du mucus et ou de la température) pour que le soutien de la progestérone (et/ou des estrogènes) ait toute son efficacité
... lire plus sur ce sujet dans un nouvel onglet.... | | Source: T. Hilgers The M and S practice of Naprotechnology |
| Référence associée : | | |
| Comparative Trials of New Oral Progestogenic Compounds in Treatment of Premenstrual Syndrome .. cacher .... voir plus ..
... lire plus sur ce sujet dans un nouvel onglet.... | | |  |
| Premenstrual syndrome: current knowledge and management. .. cacher .... voir plus ..
Premenstrual syndrome (PMS) has become a popular self-diagnosis. Faulty research has led to confusion about the diagnosis, epidemiologic features, causes and treatment of this disorder. There is no proof that the premenstrual period is a time of increased violence. An association between menstrually related mood disorders and other psychiatric illness is also unproven. Despite many theories no definitive cause of PMS has been established, and controlled studies of various treatments have failed to find a universally effective approach. Conservative measures involving support, diet and exercise seem to help in most cases. The use of alprazolam and mefenamic acid may help some women. Rectal or vaginal progesterone therapy has been proven ineffective and should not be used.
... lire plus sur ce sujet dans un nouvel onglet.... | | | |
| Prescribing patterns in premenstrual syndrome .. cacher .... voir plus ..
Background Over 300 therapies have been proposed for premenstrual syndrome. To date there has been only one survey conducted in the UK of PMS treatments prescribed by GPs, a questionnaire-based study by the National Association of Premenstrual Syndrome in 1989. Since then, selective serotonin re-uptake inhibitors have been licensed for severe PMS/PMDD, and governmental recommendations to reduce the dosage of vitamin B6 (the first choice over-the-counter treatment for many women with PMS) have been made. This study investigates the annual rates of diagnoses and prescribing patterns for premenstrual syndrome (1993–1998) within a computerised general practitioner database. Methods Retrospective survey of prescribing data for premenstrual syndrome between 1993–1998 using the General Practice Research Database for the West Midlands Region which contains information on 282,600 female patients Results Overall the proportion of women with a prescription-linked diagnosis of premenstrual syndrome has halved over the five years. Progestogens including progesterone were the most commonly recorded treatment for premenstrual syndrome during the whole study period accounting for over 40% of all prescriptions. Selective serotonin-reuptake inhibitors accounted for only 2% of the prescriptions in 1993 but rose to over 16% by 1998, becoming the second most commonly recorded treatment. Vitamin B6 accounted for 22% of the prescriptions in 1993 but dropped markedly between 1997 and 1998 to 11%. Conclusions This study shows a yearly decrease in the number of prescriptions linked to diagnoses for premenstrual syndrome. Progestogens including progesterone, is the most widely prescribed treatment for premenstrual syndrome despite the lack of evidence demonstrating their efficacy.
... lire plus sur ce sujet dans un nouvel onglet.... | | | |
| Critical evaluation of nutritional factors in the pathophysiology and treatment of premenstrual syndrome .. cacher .... voir plus ..
... lire plus sur ce sujet dans un nouvel onglet.... | | | |
| Differential Behavioral Effects of Gonadal Steroids in Women with and in Those without Premenstrual Syndrome .. cacher .... voir plus ..
Premenstrual syndrome is a cyclical disorder characterized by mood-related and somatic symptoms that occur during the luteal phase of the menstrual cycle and disappear at or soon after the onset of menstruation. The pathophysiologic role of the luteal phase in premenstrual syndrome is unclear, as are the roles of the ovarian steroids estrogen and progesterone. Truncation of the luteal phase with the progesterone-receptor antagonist mifepristone does not alter the symptoms of the syndrome,1 but ovarian suppression with agonist analogues of gonadotropin-releasing hormone usually reduces them.2–5 Taken together, these results are consistent with the view that premenstrual syndrome is triggered . . .
... lire plus sur ce sujet dans un nouvel onglet.... | | | 
|
| Puerperal and premenstrual depression. .. cacher .... voir plus ..
... lire plus sur ce sujet dans un nouvel onglet.... | | | |
| Premenstrual Syndrome: Approaches to Diagnosis and Treatment .. cacher .... voir plus ..
There has been much confusion in the literature over the definition, diagnosis and treatment of premenstrual syndrome (PMS). This article discusses definitions of PMS, incidence, etiology and symptomatology. Diagnosis depends on the timing of symptoms rather than the type. Symptoms commonly occur during the late premenstruum; at ovulation and during the premenstruum; or at ovulation, gradually increasing in severity throughout the luteal phase. To diagnose PMS, three consecutive menstrual cycles must be charted, the symptoms must be limited to the luteal phase, and there must be a complete absence of symptoms for at least one week in the postmenstruum. Rational treatment programs for mild, moderate and severe PMS are proposed. The role of progesterone in treatment is discussed.
... lire plus sur ce sujet dans un nouvel onglet.... | | | |
| Premenstrual tension syndrome. .. cacher .... voir plus ..
... lire plus sur ce sujet dans un nouvel onglet.... | | | |
| Bénéfice du pessaire à la progestérone pour le syndrome prémentruel .. cacher .... voir plus ..
Magill PJ. Investigation of the efficacy of progesterone pessaries in the relief of symptoms of premenstrual syndrome. progesterone Study Group. Br J Gen Pract. 1995 Nov;45(400):589-93.
... lire plus sur ce sujet dans un nouvel onglet.... | | |
|
| Effect of a nutritional supplement, optivite, on symptoms of premenstrual tension .. cacher .... voir plus ..
Using a menstrual symptom questionnaire (MSQ) to assess the presence and severity of premenstrual tension (PMT), we evaluated the effect of a nutritional supplement, Optivite, on PMT symptoms in 31 patients for the week after the period (F) and the week before it (L). The total MSQ scores decreased significantly in all patients after Optivite administration at a daily dose of 3-12 tablets for one to six menstrual cycles. The mean +/- S.E. total MSQ scores were F = 8.1 +/- 1.8 and L = 31.5 +/- 2.1 for control cycles and F = 2.3 +/- 0.72 and L = 10.3 +/- 1.4 for treated cycles. The best responses were observed in patients taking 6-12 tablets/day for three or more cycles. If these results can be confirmed by well-controlled studies, this simple and safe nutritional approach can be recommended in the initial management of PMT.
... lire plus sur ce sujet dans un nouvel onglet.... | | | |
| Premenstrual mood changes in affective disorders. .. cacher .... voir plus ..
Mood changes during the premenstrual phase have been the focus of considerable research in recent years. Although there has been significant progress in the diagnosis and etiology of major affective disorders, the relation between these disorders and menstrual changes remains controversial. There have been contradictory reports and speculations on women s susceptibility to psychiatric disorders during the premenstrual phase. We describe three patients with a history of mood swings associated with menstruation in whom major affective disorders developed, necessitating intensive psychiatric treatment or admission to hospital. Among women who manifest menstrual mood changes, manic-depressive illness may develop only in a subgroup with genetic predisposition. In such cases the possibility of postpartum mania or depression should be kept in mind in follow-up.
... lire plus sur ce sujet dans un nouvel onglet.... | | | |
| Douglas S. Le syndrome prémenstruel. Traitement basé sur les preuve en médecine praticienne .. cacher .... voir plus ..
... lire plus sur ce sujet dans un nouvel onglet.... | | |
|
| Alprazolam in the treatment of two subsamples of patients with late luteal phase dysphoric disorder: a double-blind, placebo-controlled crossover study .. cacher .... voir plus ..
OBJECTIVE: To assess the efficacy of alprazolam in the treatment of two groups of patients diagnosed with late luteal phase dysphoric disorder (LLPDD). The first group met only the diagnostic criteria for LLPDD. The second group experienced LLPDD and mild symptoms of anxiety and depression during the follicular phase. METHODS: A double-blind, placebo-controlled crossover design was used. Patients were treated with alprazolam and placebo for 3 months each and completed daily measures of anxiety, tension, depression, irritability, and feelings of being out of control. RESULTS: The response to alprazolam differed significantly by group. For the first group, alprazolam (0.25 mg three times a day) relieved the severity of tension (P = .001), irritability (P = .005), anxiety (P = .008), and feelings of being out of control (P = .012) more than placebo. Few side effects were reported; the incidence (P = .001) and severity (P = .001) of side effects were dose-related. Alprazolam and placebo did not differ for the second group, and the incidence and severity of side effects were unrelated to dose. CONCLUSIONS: Alprazolam benefits women diagnosed solely with LLPDD. It is not recommended for patients who experience LLPDD as well as symptoms of mild anxiety or depression during the follicular phase.
... lire plus sur ce sujet dans un nouvel onglet.... | | | |
| Comparing the Effects of Echinophora-platyloba, Fennel and Placebo on Pre-menstrual Syndrome .. cacher .... voir plus ..
Introduction Premenstrual syndrome (PMS) is a condition characterized by a number of behavioral, psychological and physical symptoms recurring cyclically during the luteal phase of the menstrual cycle. The uncertainty in the pathogenesis of PMS has led to many treatment protocols being suggested as possible therapies. The present study was carried out to compare the effects of echinophora-platyloba and fennel extracts on the PMS against placebo in students of Shahrekord University of Medical Sciences in 2008. Methods In this single-blind randomized clinical trial, 90 students with moderate to severe PMS enrolled in the study and were randomely divided into three equal groups. The first group received echinophora-platyloba extract, the second group received fennel extracts and the third group received placebo. The severity of PMS was measured by Daily Record of Severity of Problems (DRSP) questionnaire at the end of the first and second menstrual cycles before the intervention and the results were compared with them after the intervention. Data was analyzed using Dunn, Kruskal Wallis, and Pearson correlation tests by SPSS (v. 11.5) and p < 0.05 was considered statistically significant. Results There were not any significant differences in the means of premenstrual syndrome scores before the intervention among the three groups (100.8±22.1 in echinophora-platyloba group, 101.3±27.1 in fennel group and 104.3±19.5 in placebo group, p > 0.05), but the differences were significant after the intervention (49.7±23.2 in echinophora-platyloba group, 64.4±27.5 in fennel group and 79.1±28.1 in placebo group, respectively, p < 0.001). No significant differences were seen between the echinophora-platyloba and fennel groups. Conclusion The echinophora-platyloba and fennel extracts could reduce the severity of PMS. The effects of echinophora-platyloba and fennel were similar and greater than the placebo. Administration of the extracts of these herbs is suggested for relieving the signs and symptoms of PMS.
... lire plus sur ce sujet dans un nouvel onglet.... | | | |
| A Double-blind Trial of Oral Progesterone, Alprazolam, and Placebo in Treatment of Severe Premenstrual Syndrome .. cacher .... voir plus ..
Objective.—To determine the effectiveness of oral micronized progesterone, alprazolam, and placebo in premenstrual syndrome (PMS) treatment and the effect of clinical contact on treatment responses. Design.—Randomized, double-blind, placebo-controlled 3-month parallel treatment arms with flexible dosage and with the length of clinical contact randomized within each treatment group. Setting.—University hospital PMS medical treatment outpatient program in obstetrics/gynecology department. Subjects.—Among volunteers for PMS treatment, 444 were evaluated and 185 meeting defined PMS criteria were randomized to treatment; treatment data are available for 170. There were no medical withdrawals for adverse events. Intervention.—A double-blinded protocol in which 300 mg of oral micronized progesterone, 0.25 mg of alprazolam, or placebo was administered four times a day from day 18 of the menstrual cycle through day 2 of the next cycle, including taper. The mean daily dose at the third treatment was 1760 mg of progesterone or 1.5 mg of alprazolam. Subjects were randomized to brief (<20 minutes) or extended (50 minutes) visits. Main Outcome Measures.—Daily symptom report (DSR) scored for total DSR symptoms, four DSR factors. Results.—Alprazolam was significantly better than placebo or progesterone for total premenstrual symptoms and DSR factors of mental function, pain, and mood. Thirty-seven percent of the alprazolam group experienced a 50% reduction in total DSR scores. There were no clinically significant withdrawal symptoms when alprazolam administration was restricted to the luteal phase. Oral micronized progesterone therapy was no better than placebo. Brief vs extended visits had no effect on treatment outcome. Treatment response was associated with severity of premenstrual symptoms at baseline but with no other diagnostic variables. Conclusions.—Alprazolam has a role in PMS treatment and offers a therapy limited to the luteal phase. Oral micronized progesterone is ineffective for PMS. (JAMA. 1995;274:51-57)
... lire plus sur ce sujet dans un nouvel onglet.... | | | |
| Efficacité de la progesterone et des progestagens dans le traitement du syndrome prémentruel .. cacher .... voir plus ..
... lire plus sur ce sujet dans un nouvel onglet.... | | |
|
| Estrogenic and Progestagenic effects of extracts of Justicia pectoralis Jacq., an herbal medicine from Costa Rica used for the treatment of Menopause and PMS .. cacher .... voir plus ..
Objectives To investigate the biological activities of Justicia pectoralis Jacq. (Acanthaceae), an herbal medicine used in Costa Rica (CR) for the management of menopausal symptoms and dysmenorrhea. Study design The aerial parts of Justicia pectoralis were collected, dried and extracted in methanol. To establish possible mechanisms of action of JP for the treatment of menopausal symptoms, the estrogenic and progesterone agonist, and antiinflammatory activities were investigated. Main outcome measures The methanol extract (JP-M) was tested in ER and PR binding assays, a COX-2 enzyme inhibition assay, the ERβ-CALUX assay in U2-OS cells, as well as reporter and endogenous gene assays in MCF-7 K1 cells. Results The JP-M extract inhibited COX-2 catalytic activity (IC50 4.8µg/ml); bound to both ERα and ERβ (IC50 50 µg/ml and 23.1µg/ml, respectively); induced estrogen-dependent transcription in the ERβ-CALUX; and bound to the progesterone receptor (IC50 22.8 µg/ml). The extract also modulated the expression of endogenous estrogen responsive genes pS2, PR, and PTGES in MCF-7 cells at a concentration of 20 µg/ml. Activation of a 2 ERE-construct in transiently transfected MCF-7 cells by the extract was inhibited by the estrogen receptor antagonist ICI 182,780, indicating that the effects were mediated through the estrogen receptor. Finally, the extract weakly enhanced the proliferation of MCF-7 cells, however this was not statistically significant as compared with DMSO controls. Conclusions Extracts of J. pectoralis have estrogenic, progestagenic and anti-inflammatory effects, and thus have a plausible mechanism of action, explaining its traditional use for menopause and PMS.
... lire plus sur ce sujet dans un nouvel onglet.... | | |
|
| The psychobiology of premenstrual dysphoria: review of theories and treatments .. cacher .... voir plus ..
(1) Premenstrual mood changes such as depression, elation, anxiety, hostility and irritability are a common cause of disability in women. (2) The nature of the disorder, the clinical dimensions, the incidence, the psychological and psychosocial theories are reviewed. (3) A long list of treatments recommended over the years is also reviewed and discussed, illustrating the ambiguity and uncertainty in this area. (4) The relationship to other periodic functional conditions, especially manic-depressive illness is discussed with particular emphasis on predictive studies.
... lire plus sur ce sujet dans un nouvel onglet.... | | | |
| Cette étude montre une amélioration significative des symptômes grâce à une administration ciblée et programmée de progestérone par l’étude du cycle menstruel.
Dennerstein L, Spencer-Gardner C, Gotts G, Brown JB, Smith MA, Burrows GD: Proges t er one and the
Premenstrual Syn drome: A Double-Blind Cross-Over Tri al. BMJ 290:1617-1621, 1985. .. cacher .... voir plus ..
... lire plus sur ce sujet dans un nouvel onglet.... | | |
| Comparing the Effects of
Echinophora-platyloba, Fennel and Placebo on Pre-menstrual Syndrome. .. cacher .... voir plus ..
... lire plus sur ce sujet dans un nouvel onglet.... | | |
|
| Non-Antidepressant Treatment of Premenstrual Syndrome .. cacher .... voir plus ..
... lire plus sur ce sujet dans un nouvel onglet.... | | |
| Beta endorphine significativement diminuée dans la phase post-ovulatoire
Facchinetti F, Martignoni E, Petraglia F, Sances MG, Nappi G, Genazzani AR: Pre men stru al Fall of
-endorphin in Pa tients with Premenstrual Syndrome. Fertil Steril 47:570-573, 1987. .. cacher .... voir plus ..
... lire plus sur ce sujet dans un nouvel onglet.... | | |
| Investigation of the efficacy of progesterone pessaries in the relief of symptoms of premenstrual syndrome. progesterone Study Group. .. cacher .... voir plus ..
BACKGROUND. A variety of definitions have been applied to premenstrual syndrome. The severity of the syndrome is also variable. AIM. A study was undertaken to compare progesterone pessaries with placebo in the relief of symptoms of premenstrual syndrome. In this study the condition was characterized by a wide range of symptoms recurring in the late luteal phase but absent in the follicular phase (that is, the specific definition published by Dalton in 1953). METHOD. A multicentre, prospective, double-blind, randomized, parallel group study was undertaken by 45 general practitioners. Patients were deemed eligible after two prospective menstrual cycles of observation (selection phase) in which a precise definition of symptoms was applied. Patients were randomized to use either progesterone pessaries (400 mg twice a day) or matching placebo, by vaginal or rectal administration, from 14 days before the expected onset of menstruation until the onset of vaginal bleeding, for four consecutive cycles. Baseline data for the outcome variables were determined in the selection phase. The main outcome variables were changes in the severity (categorized as none, mild, moderate or severe) of each patient s most severe symptom, and in the average score of all the patient s symptoms characteristic of premenstrual syndrome. Spontaneous reports of adverse events were recorded. RESULTS. A total of 281 patients were screened for premenstrual syndrome; of these, 141 patients were randomized to treatment or placebo groups. Efficacy was evaluated in 93 patients. Reductions in the scores of the highest scoring, most severe, symptoms and in the average symptom score, were consistently observed in patients receiving progesterone pessaries and in those receiving placebo. The response to progesterone was greater than to placebo during each cycle; the differences were clinically and statistically significant. Adverse events were reported by 51% of patients in the progesterone treatment group and by 43% in the placebo group. Irregularity of menstruation, vaginal pruritus and headache were reported more frequently by patients taking active therapy. CONCLUSION. In this study, progesterone, given as pessaries by vaginal or rectal administration, was more effective than placebo in the relief of symptoms of premenstrual syndrome in a population of patients selected by strict entry criteria.
... lire plus sur ce sujet dans un nouvel onglet.... | | | |
| Diagnosis and Treatment of Premenstrual Dysphoria .. cacher .... voir plus ..
... lire plus sur ce sujet dans un nouvel onglet.... | | |
| Progesterone and the premenstrual syndrome: a double blind crossover trial. .. cacher .... voir plus ..
A double blind, randomised, crossover trial of oral micronised progesterone (two months) and placebo (two months) was conducted to determine whether progesterone alleviated premenstrual complaints. Twenty three women were interviewed premenstrually before treatment and in each month of treatment. They completed Moos s menstrual distress questionnaire, Beck et al s depression inventory, Spielberger et al s state anxiety inventory, the mood adjective checklist, and a daily symptom record. Analyses of data found an overall beneficial effect of being treated for all variables except restlessness, positive moods, and interest in sex. Maximum improvement occurred in the first month of treatment with progesterone. Nevertheless, an appreciably beneficial effect of progesterone over placebo for mood and some physical symptoms was identifiable after both one and two months of treatment. Further studies are needed to determine the optimum duration of treatment.
... lire plus sur ce sujet dans un nouvel onglet.... |  | |
|
| Comparative trials of new oral progestogenic compounds in treatment of premenstrual syndrome .. cacher .... voir plus ..
... lire plus sur ce sujet dans un nouvel onglet.... | | |
|
| Steiner M, Steinberg S, Stewart D, Cart er D, Berger C, Reid, et al: Fluoxetine in the Treatment of Premenstrual
Dys pho ria. N Engl J Med 332:1529-1534, 1995. .. cacher .... voir plus ..
... lire plus sur ce sujet dans un nouvel onglet.... | | |
| Conditioning exercise
decreases premenstrual symptoms: a prospective, controlled 6-month trial. .. cacher .... voir plus ..
... lire plus sur ce sujet dans un nouvel onglet.... | | | |
| Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study .. cacher .... voir plus ..
Objectives To compare the efficacy and tolerability of agnus castus fruit (Vitex agnus castus L extract Ze 440) with placebo for women with the premenstrual syndrome. Design Randomised, double blind, placebo controlled, parallel group comparison over three menstrual cycles. Setting General medicine community clinics. Participants 178 women were screened and 170 were evaluated (active 86; placebo 84). Mean age was 36 years, mean cycle length was 28 days, mean duration of menses was 4.5 days. Interventions Agnus castus (dry extract tablets) one tablet daily or matching placebo, given for three consecutive cycles. Main outcome measures Main efficacy variable: change from baseline to end point (end of third cycle) in women s self assessment of irritability, mood alteration, anger, headache, breast fullness, and other menstrual symptoms including bloating. Secondary efficacy variables: changes in clinical global impression (severity of condition, global improvement, and risk or benefit) and responder rate (50% reduction in symptoms). Results Improvement in the main variable was greater in the active group compared with placebo group (P<0.001). Analysis of the secondary variables showed significant (P<0.001) superiority of active treatment in each of the three global impression items. Responder rates were 52% and 24% for active and placebo, respectively. Seven women reported mild adverse events (four active; three placebo), none of which caused discontinuation of treatment. Conclusions Dry extract of agnus castus fruit is an effective and well tolerated treatment for the relief of symptoms of the premenstrual syndrome.
... lire plus sur ce sujet dans un nouvel onglet.... | | | |
| Symptome concerné : | | |
| Symptômes du syndrome pré menstruel .. cacher .... voir plus ..
Un aspect important du diagnostic est le fait que ces symptômes doivent débuter au moins quatre jours avant le début des règles. Si elles surviennent dans les trois jours suivant l'apparition des règles, elles sont considérées comme des symptômes prémenstruels normaux.
Les symptômes physiques du SPM peuvent inclure:
Tension et sensibilité des seins
Ballonnements abdominaux
La rétention d'eau
Constipation ou diarrhée
Maux de tête et migraine
Augmentation de l'appétit et du gain de poids
Acné
Douleurs musculaires et articulaires
Les symptômes émotionnels et comportementaux de SPM peuvent inclure:
Dépression
Anxiété et tension
L'insomnie ou le sommeil
Changement d'intérêt et de désir sexuel
Irritabilité
L'hostilité et les éclats de colère
Saut de l'humeur
Incapacité de se concentrer
Pleurs
Léthargie et fatigue
... lire plus sur ce sujet dans un nouvel onglet.... | | |
Médecine par les plantes, la nutrition et l'activité, mode de vie, acupuncture